Centers | ||
|
|
|
EU-OPENSCREEN | Drug Discovery Unit | Chulalongkorn University Drug Discovery and Drug Development Research Center (Chula4DR) |
EU-OPENSCREEN is a multinational, not-for-profit initiative, which
integrates high-capacity screening platforms and chemistry groups across
Europe. The aim of this initiative is to support individual scientists
interested in chemical biology... |
The Drug Discovery Unit (DDU) is a fully integrated drug discovery group established to translate world-class biology research into novel drug targets and candidate drugs. Housed within purpose built facilities at the University of Dundee, the DDU... Read more |
Chulalongkorn
Drug Discovery and Drug Development Research Center (Chula4DR) was
established in 2017, with the aim to facilitate advancement of academic
drug discovery and drug development research by leveraging innovations
and sciences... Read more |
Partnerships |
Events |
Jobs |
Johns Hopkins BSi Licenses GCPII Assets from EisaiJohns Hopkins Brain Science Institute ("BSi") has taken a non-exclusive license from Eisai to develop new compounds related to Glutamate Carboxypeptidase II (GCP-II) technology. The new compounds developed under this license will be targeted... View all Royal Society of Chemistry
Led by Hiroaki Suga (University of Tokyo), RSC Chemical Biology is a gold open access journal, dedicated to publishing exceptionally significant and breakthrough findings of interest to the chemical biology... View all Sanofi and Joslin Diabetes Center to Develop New Drugs for Diabetic CareJoslin Diabetes Center a teaching and research affiliate of Harvard Medical School and Sanofi have entered into a partnership agreement to develop new drugs to treat diabetes. Under this collaboration, Sanofi will have the right to commercialize... View all |
No EVENTS for listing |
No Job Posts |
